Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

BRIEF-Valeant Pharmaceuticals gets notice of default from bondholders

Published 2016-05-19, 06:05 p/m
© Reuters.  BRIEF-Valeant Pharmaceuticals gets notice of default from bondholders
BHC
-

May 20 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX)
* Valeant pharmaceuticals receives notice of default from
bondholders
* Says Company Has Until July 18, 2016 To Cure Default By
Filing Form 10 VRX.TO
* Notice of default does not result in acceleration of any
of Valeant's indebtedness
* Continues to expect to file form 10-Q on or before June
10, 2016
* Expects to file form 10-Q with Securities And Exchange
Commission and Canadian securities regulators on or before June
10, 2016
* Under senior note indenture, co has 60 days from receipt
of notice to file form 10-q, which will cure default in all
respects

Source text for Eikon: ID:nPn7GJ4Xfa
Further company coverage: VRX.TO

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.